The asthma and chronic obstructive pulmonary disease (COPD) market represents a brand-dominated market that could face substantial changes over the next few years by the possible arrival of generic medications as well as the launch of several new monotherapies and combination therapies. Approximately 10 million Americans are currently diagnosed with COPD (although the actual number suffering from this condition could be several million more). Another 22 million are diagnosed with asthma, generating billions of dollars in healthcare expenses. Those suffering from these conditions can take monotherapy medications that include both long and short-acting beta-2 agonists (SABAs) as well as long-acting muscarinic antagonists and inhaled corticosteroids (ICSs). Major brands will have to contend with the expected rise of branded generic therapies of GlaxoSmithKline's Flovent (fluticasone) and Advair (salmeterol/fluticasone propionate), which may drive payors to tighten their formularies and cover expensive branded therapies on Tier 3 or higher. Drug manufacturers are reacting to this prospect by developing new therapies that offer improved administration over existing therapies and by combining various types of drugs to boost their effectiveness. With multiple drugs slated to launch featuring similar combinations, the COPD and asthma market may see intense competition centered on these new therapies.

Using tiering and restrictions data from Fingertip Formulary, as well as insight from 47 pharmacy directors, this report determines the key trends in reimbursement of immune biologics, drivers of these trends, and how stakeholders can capitalize on future shifts in coverage to steal share from the competition.

Related Reports

Formulary Advantages in Type 2 Diabetes:Rebates and discounts dictate the formulary position of branded therapies among some U.S. health plans.

According to the Centers for Disease Control and Prevention (CDC), an estimated 25.8 million people in the United States have diabetes. Diabetes is the leading cause of kidney failure, nontraumatic lo...

View Details

Formulary Advantages in Atrial Fibrillation: How Will MCO Size Affect the Design of Factor Xa Formularies?

In the coming years, atrial fibrillation (AF) patients will increasingly have more choice for anticoagulation therapy. Although Boehringer Ingelheim’s Pradaxa (dabigatran etexilate) and emerging facto...

View Details

Formulary Advantages in Asthma and COPD Therapies: Formulary Advantages in Asthma and COPD Therapies - Abstract

The market for asthma and chronic obstructive pulmonary disease (COPD) has grown notably in recent years because of increasing prevalence and diagnosis rates for both conditions as well as the greater...

View Details

Formulary Advantages in Psychiatric Drugs: Medicare plans readily employ cost-sharing measures and formulary restrictions to direct early use of generics and preferred brands for psychiatry.

According to the National Institute of Mental Health, each year tens of millions of Americans are affected by mental illness. Although significant strides have been made toward understanding the patho...

View Details